rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    LGVN
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Longeveron LLC earnings missed by $0.28, revenue fell short of estimates
      Nov 13Investing.comLGVN
      Longeveron Announces 2026 Third Quarter Financial Results and Provides Business Update
      Nov 12Yahoo FinanceLGVN
      Longeveron Announces Engagement of Lucid Capital Markets

      MIAMI, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (the “Company”) (NASDAQ: LGVN), today announced that the Company has retained Lucid Capital Markets, LLC as the Company’s financial advisor to explore potential strategic opportunities, including a potential business combination. About Longeveron Inc. Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is laromestrocel (Lomecel-B®)

      Oct 28Yahoo FinanceLGVN
      Longeveron (LGVN) Heart Treatment Falls Short. Can a Strategic Review Preserve Value?

      Longeveron Inc. (NASDAQ:LGVN) reported on September 16 that ELPIS II, its randomized Phase 2b trial in 40 infants with hypoplastic left heart syndrome, missed its primary efficacy endpoint. The study evaluated laromestrocel as an adjunct to Stage 2 palliative heart surgery. The primary endpoint measured change in right ventricular ejection fraction, an indicator of pumping […]

      Sep 22Yahoo FinanceLGVN
      Longeveron stock plunges 50% after trial misses primary endpoint
      Sep 17Investing.comLGVN
      Top Midday Decliners
      Sep 17Yahoo FinanceLGVN
      Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)
      Sep 16Yahoo FinanceLGVN
      Longeveron Regains Nasdaq Compliance With Minimum Bid Price

      Detailed price information for Longeveron Inc (LGVN-Q) from The Globe and Mail including charting and trades.

      Sep 15The Globe and MailLGVN
      Longeveron to Present at the H.C. Wainwright 28th Annual Global Investment Conference

      MIAMI, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will participate in the H.C. Wainwright 28th Annual Global Investment Conference taking place September 14-16, 2026 in New York City. Details for the Company’s presentation: Date:Monday, September 14, 2026 Time:1:00 – 1:30 p.m. ET The webcast for this

      Sep 3Yahoo FinanceLGVN
      Longeveron Announces 1-for-10 Reverse Stock Split

      Longeveron Announces 1-for-10 Reverse Stock Split

      Aug 24BarchartLGVN

      This is the newest page. Registered accounts read further back.